Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 6.3% – Still a Buy?
by Kim Johansen · The Markets DailyAutolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) shot up 6.3% during mid-day trading on Monday . The company traded as high as $2.25 and last traded at $2.2850. 381,911 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 1,748,486 shares. The stock had previously closed at $2.15.
Analysts Set New Price Targets
Several analysts have commented on AUTL shares. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.
Read Our Latest Stock Analysis on AUTL
Autolus Therapeutics Trading Up 5.8%
The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. The stock’s fifty day moving average is $1.64 and its 200 day moving average is $1.57. The stock has a market cap of $605.51 million, a P/E ratio of -2.15 and a beta of 2.07.
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The company had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. As a group, equities research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after acquiring an additional 8,309 shares during the period. Independent Advisor Alliance bought a new position in Autolus Therapeutics during the 4th quarter valued at about $28,000. Marex Group plc bought a new position in Autolus Therapeutics during the 2nd quarter valued at about $28,000. Waverly Advisors LLC purchased a new stake in Autolus Therapeutics in the 1st quarter worth about $37,000. Finally, SmartHarvest Portfolios LLC bought a new stake in Autolus Therapeutics in the fourth quarter worth about $43,000. Institutional investors own 72.83% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.